Antaros Medical receives Vinnova funding to develop unique imaging tool for better diagnosis and treatment of patients with chronic kidney disease

Today, Vinnova announced that Antaros Medical is one of the companies that receives funding through the call Innovationsprojekt i företag, […]

Gadoxetate DCE-MR imaging – exciting results on the validation of gadoxetate as a biomarker of liver function

Today, the ILSI-HESI Translational Imaging Liver project published new, exciting data in Plos-one, A multi-center preclinical study of Gadoxetate DCE-MRI […]

Career Opportunity – Accounting Manager

Would you like to work in an innovative biotech company characterized by an entrepreneurial and inspiring spirit? A company, where […]

Career Opportunity – MRI Site Specialist

Would you like to work in an innovative biotech company characterized by an entrepreneurial and inspiring spirit? A company, where […]

Antaros partner in ground-breaking European project concerning biomarkers for liver disease

LITMUS, a pioneering 34 million Euro research collaboration to develop new and non-invasive biomarkers for better diagnoses of patients with […]

Importance of High Precision Imaging Biomarkers in NASH Drug Development

Dr Lars Johansson, CSO, and one of the founders of Antaros, presented at the NASH Summit in Frankfurt, October 11-12. […]

Antaros Medical presents First-in-class PET tracer for the glucagon receptor at EASD 2017

Lisbon, 12 September Antaros Medical, in collaboration with Sanofi, presents important data at the 53rd Annual Meeting of the European […]

Antaros Medical presents data supporting Imiomics at the ESMO 2017 Congress

Madrid, 11 September Together with teams at Uppsala University, Antaros presented a poster with the title “Registration based automated lesion […]

Antaros Medical presented data at the 2nd NASH biomarkers workshop on the importance of assessing the entire liver when studying liver fat

Assoc Professor Lars Johansson, co-founder of Antaros Medical and Chief Scienctific Officer, together with Dr Chris Weyer, President and Chief […]

Antaros – partner in EU IMI collaboration TRISTAN focusing on imaging biomarkers for drug safety assessments

The EU Innovative Medicines Initiative (IMI) has approved TRISTAN, a 5-year project focusing on validation of translational imaging methods for […]